IPO早知道·2025-06-05 20:51Core Viewpoint - The collaboration between Zhixiang Jintai and Cullinan Therapeutics aims to accelerate the global development of GR1803, a bispecific antibody for treating relapsed/refractory multiple myeloma, marking a significant milestone in Zhixiang Jintai's global strategy and innovation transformation [2]. Group 1 - Zhixiang Jintai announced an overseas licensing agreement with Cullinan Therapeutics, granting Cullinan global development, production, and commercialization rights for GR1803 outside Greater China, while retaining rights in mainland China [1]. - The agreement includes an upfront payment of $20 million, potential milestone payments up to $692 million, and tiered royalties based on net sales outside Greater China [1]. - GR1803 is currently in Phase 2 clinical trials and was included in the list of breakthrough therapies by the Chinese National Medical Products Administration [2]. Group 2 - SinoMed, established in March 2022, provides business development services for biopharmaceutical companies seeking overseas collaborations, with a team experienced in cross-border licensing transactions [3]. - The SinoMed team has evaluated over 300 projects and facilitated collaborations with more than 20 domestic companies, completing transactions for three projects across various therapeutic areas [3].